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Purpose: Synoviopathy contributes to cartilage degradation in osteoarthritis (OA). Intermittent para-
thyroid hormone (PTH) [1-34] administration inhibits terminal differentiation of human chondrocytes
and prevents cartilage damage. We aimed to determine whether PTH [1-34] could modify synovial
changes in experimental OA preceded by osteoporosis (OP).
Methods: Twenty osteoporosis (OP) rabbits underwent knee surgery to induce OA. Theywere administered
either saline vehicle or PTH for 10 weeks. Ten healthy rabbits were used as controls. Following sacriﬁce,
synovial changes were assessed by Krenn synovitis score, immunohistochemistry for macrophages (RAM-
11), B and T lymphocytes, type I collagen, parathyroid hormone 1 receptor (PTH1R), and anti-proliferating
cell nuclear antigen (PCNA). Synovial mRNA levels of Col1A1, IL-1b, cyclooxygenase 2 (COX-2), matrix-
degradingmetalloproteinases (MMP-9,MMP-13), andmonocyte chemotactic protein-1 (MCP-1), aswell as
protein expression of PTH1R were also determined. Cartilage damage was analyzed by Mankin score.
Results: OPOA þ vehicle rabbits showed an increase in synovitis score vs controls (P ¼ 0.003), mainly due
to synovial hyperplasia and ﬁbrosis, while PTH reduced these changes (P ¼ 0.017). Mankin and Krenn
scores were well correlated in all groups (r ¼ 0.629, P ¼ 0.012). Immunostaining for RAM-11 and B
lymphocytes was increased (P  0.05), whereas PTH1R protein levels tended to be higher in
OPOA þ vehicle animals vs controls. PTH did not modify RAM-11 staining or PTH1R levels; however, it
restored PTH1R localization to the vicinity of synovial vessels. PTH also decreased type I collagen, MCP-1,
and MMP-13 expression (P < 0.05), as well as PCNA staining compared to vehicle-treated OPOA rabbits.
Conclusions: In our model of OA aggravated by previous OP, synoviopathy correlated well with cartilage
damage. Intermittent PTH [1-34] administration ameliorated both hyperplasia and ﬁbrosis.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) has been recently established as a disease
that affects the whole joint, including not only the articular carti-
lage and subchondral bone but also the synovial membrane1,2. In
fact, advanced noninvasive imaging techniques such as magnetic
resonance imaging (MRI) and ultrasonography (US) have made
possible the identiﬁcation of synovial changes that occur in both
patients undergoing joint replacement surgery and patients with
early OA not clinically detected3.: J.A. Roman-Blas, Bone and
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s Research Society International. PRelevant histological changes have been frequently identiﬁed in
the synovium of OA patients. Mild synovial hyperplasia with
proliferation and activation of lining cells is mostly present in early
OA4,5. Fibrotic changes may be early observed in subsynovial
stroma, often accompanying synovial villi hyperplasia6. Further
shortening and thickening of the joint capsule, a phenomenon
which is partially responsible for articular stiffness happens in late-
stage OA disease4. Afterwards, bone and cartilage fragments are
embedded in the synovial membrane during the end stage of the
disease. Fibrinous exudates at the surface of synovial membrane
and a minor inﬂammatory cell inﬁltrate have been described in this
late synoviopathy7. Synovial inﬂammatory inﬁltrates appear in far
less abundance than in rheumatoid arthritis (RA) synovium,
distributed in a patchy pattern and mostly conﬁned to areas adja-
cent to sites of damaged cartilage, thus increasing OA severity
throughout the disease process8,9. Activated macrophages are
major components of synovial OA inﬁltrates, although T and B cells
are also observed in OA synovium3,7,10,11.ublished by Elsevier Ltd. All rights reserved.
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increased production of pro-inﬂammatory cytokines andmediators
of joint damage11. In cell cultures from digested OA synovium, the
depletion of CD14 þ synovial macrophages led to signiﬁcant inhi-
bition of interleukin (IL)-1b and tumor necrosis alpha (TNF)-a
expression, thus showing that both cytokines are mainly produced
by synovial macrophages12. In addition, there was a signiﬁcant
down-regulation of pro-inﬂammatory cytokines (IL-6), chemokines
(IL-8, monocyte chemotactic protein-1 (MCP-1)), and matrix-
degrading metalloproteinases (MMP-1 and -3), mostly produced
by synovial ﬁbroblasts under the combined effects of IL-1b and
TNF-a12. Notably, histological synovial inﬂammation has been
associated with clinical symptoms as well as progression of struc-
tural changes in OA3,4,8,9. Moreover, synovitis and local concentra-
tion of pro-inﬂammatory mediators are involved in pain generation
in OA joints3,13,14.
Parathyroid hormone (PTH) [1-34], a PTH analog, has been
recently shown to inhibit the terminal differentiation of human
articular chondrocytes and reduce OA progression in papain-
induced OA in knee joints of rats15. Also, PTH-related protein
(PTHrP) production by synoviocytes was increased in OA and RA
synovial membranes, and furthermore, IL-6 secretion by synovio-
cytes was increased following incubation with PTHrP [1-34]16.
Nevertheless, no information exists about the action of exogenous
PTH on OA-associated synovitis.
Very few studies in animal models have been carried out to
explore in vivo the mechanisms underlying the contribution of
synoviopathy to development and progression of the OA process. In
fact, chronic synovial pathology has been detected after OA
induction by meniscectomy in an ovine model17. In addition, intra
articular injections of transforming growth factor (TGF)-b induced
synovial hyperplasia and osteophyte formation in amousemodel18,
and a transgenic mouse model overexpressing cathepsin K spon-
taneously developed synovitis19. We have recently demonstrated
that PTH reduced knee-cartilage damage mainly by improving
subchondral bone quality in a rabbit model of combined OA and
osteoporosis (OP)20. This experimental model induces more severe
OA lesions in the cartilage21, thus being suitable to study synovial
membrane changes in this disease.
Using a combined animal model of OA aggravated by precedent
OP, we have studied the effects of PTH [1-34] on histological
changes and on pro-inﬂammatory and degradation mechanisms
occurring in the synovial membrane, which may contribute to
cartilage damage during the OA process.
Materials and methods
Animals
Thirty skeletally mature female New Zealand rabbits
(8 months old; 3.8e4.8 kg body weight; Granja Universal, Pam-
plona, Spain) were included in this study. The animals were
handled during the study as previously reported21, in accordance
with the procedures approved by the Institutional Animal Care
and Use Committee.
Experimental animal model
OP was induced in 20 rabbits by ovariectomy (OVX) and intra-
muscular injections of methylprednisolone hemisuccinate (1 mg/
kg/day for 4 weeks; OP group). Ten additional age- and gender-
matched animals were used as controls (healthy group). After
7 weeks, surgical OA was induced in the left knee of the OP rabbits
throughmedial meniscectomy and anterior cruciate ligament (ACL)
section (OPOA group), as described in a previous protocol21. Atweek 12, OPOA rabbits were divided in two groups: 10 rabbits were
injected with saline solution (OPOA þ VEH group) and 10 rabbits
received subcutaneous injections of PTH [1-34] (10 mg/kg/day, 5
days weekly; Forsteo; Eli Lilly, Houten, Netherlands; OPOA þ PTH
group) for 10 weeks. Finally, the rabbits were euthanized by
intracardiac administration of sodium pentobarbital (50 mg/kg)
(Pentotal, Abbott, Madrid, Spain) at 22weeks after OVX. At sacriﬁce,
samples of articular cartilage, synovial membrane and subchondral
bone of each left knee were collected for further studies.
Cartilage and synovial membrane histology
After sacriﬁce, the femurs were ﬁxed in 4% paraformaldehyde
for 24 h, and then decalciﬁed for 30 days in 98% formic acid and 37%
paraformaldehyde for further histological evaluation. The decal-
ciﬁed femurs were cleaved in a sagittal plane along the central
portion of the articular surface of each medial femoral condyle
corresponding to the weight-bearing area22, and subsequently
embedded in parafﬁn wax. Cartilage sections (5 mm) were stained
with Safranin-O Fast Green to evaluate cartilage abnormalities
using a modiﬁed Mankin score23.
Articular cavity is reached by sectioning patellar tendon and
taking out the patella, thus the entire subpatellar synovial
membrane is obtained for further analysis. Following, a half of
synovial membrane containing both stroma and lining was ﬁxed in
4% paraformaldehyde for 24 h and then embedded in parafﬁn wax
after being washed with 70% ethanol. Synovium sections (5-mm
thick) were stained with hematoxylin and eosin to perform Krenn
grading of chronic synovitis24. This score is used to assess every
kind of synovitis in conventionally stained routine sections. It
evaluates three relevant morphological alterations of chronic
synovitis: hyperplasia or enlargement of synovial lining cell layer,
matrix and vessel changes related to ﬁbrosis and inﬂammatory
inﬁltration. Each feature is graded separately from 0 (absent) to 3
(strong), and then a ﬁnal score (0e9) is obtained from the sum of
each partial grade24.
Furthermore, an additional assay was carried out to have an
accurate estimate of synovial lining thickness by measuring the
thickness of the synovial membranes in pixels using the image
analysis program Image J version 1.45 (National Institute of Mental
Health, Bethesda, MD, USA). More precisely, the thickness of four
representative and randomly chosen lining sites were measured
within a length of 600 pixels in three 20 pictures of each synovial
membrane. Thus, a total lining length of 1,800 pixels per synovial
membrane was measured, and a total of 12 measurements per
membrane have been assessed to calculate the mean lining thick-
ness per synovial membrane.
Subchondral bone microstructural assessment
Several procedures were carried out to examine subchondral
bone microstructure, as previously described21. Brieﬂy, cylindrical
biopsies of subchondral bone measuring 9 mm of length by 4 mm
in diameter from femoral condyles were extracted with a trepan
bur for explantation (Group Komet, Lemgo, Germany). Further
study of microarchitecture of the samples was performed bymicro-
computerized tomography (mCT; Skyscan 1172; Skyscan, Aartse-
laar, Belgium). Using the reconstruction software NRecon
(Skyscan), the image slices were reconstructed applying corrections
for bean hardening and ring artifacts. The regions of interest
selected were analyzed with CTAn software (Skyscan). Two-
dimensional (2D) variables including tissue area (T.Ar), bone area
(B.Ar), bone area/tissue area fraction (B.Ar/T.Ar%), trabecular
thickness (Tb.Th), fractal dimension (FD) and polar moment of
inertia (Ip) were determined for selected regions.
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Tissue from synovial membranes was homogenized in liquid
nitrogen, and total RNA was extracted from the resulting powder
using Tripure isolation reagent (Roche Applied Science, Indian-
apolis, USA), in accordance with the manufacturer’s instructions.
First-strand cDNAwas synthesized from 1 mg of total RNA using the
High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
Stockholm, Sweden). PCR primers and probes for IL-1b, cyclo-
oxygenase 2 (COX-2), collagen, type I, alpha 1 (Col1A1), MMP-9,
MMP-13, and MCP-1 genes were designed by Applied Biosystems.
The endogenous controls in these assays were the eukaryotic 18S
rRNA and rabbit glyceraldehyde 3-phosphate dehydrogenase
(GAPDH). Thermal cycling and ﬂuorescence detection were per-
formed with the StepOne Plus Detection System using the StepOne
Plus v2.2 software (Applied Biosystems). Denaturation was carried
out for 10 min at 95C followed by 40 cycles of 15 s at 95C and
1 min at 60C. Target gene expression relative to the healthy group
was then estimated by the DDCt method.
Western-blot analysis
For parathyroid hormone 1 receptor (PTH1R) detection, 25 mg of
each sample were heated to 95C for 5 min and then resolved on
a 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) gel. The proteins were transferred to methanol-wetted
polyvinylidene diﬂuoride (PVDF) membrane in Tris/Glycine trans-
fer buffer. Following this, the membranes were blocked for 1 h at
room temperature in blocking buffer (5% skim milk powder, 0.5%
Tween 20 in Tris Buffered Saline-TBS). An antibody against PTH1R
(Abcam, Cambridge, UK) was incubated overnight at 4C. The blots
were washed in Tris-Buffered Saline plus Tween 20 TBST buffer
(0.3% Tween 20 in TBS) for 10 min  3 times. Antibody binding was
detected by enhanced chemoluminiscence (Immobilon, Millipore,
Billerica, MA, USA) using peroxidase-labeled secondary antibody
incubated for 1 h at room temperature. The blots were exposed to
X-ray ﬁlm. Finally, the densitometry results were expressed in
arbitrary units (AU) normalized to b-actin levels.
Immunohistochemistry
Entire synovial membranes, including stroma and lining zones
were taken for immunohistochemical studies. Monoclonal anti-
rabbit macrophage antibody (RAM11; DakoCytomation, Glostrup,
Denmark), mouse anti-human CD79a (as a marker for B lympho-
cytes; BD, Franklin Lakes, NJ, USA), mouse monoclonal anti-rabbit T
cell marker (KEN-5; Santa Cruz Biotechnology Inc, Santa Cruz, CA,
USA), mouse monoclonal anti-PTH1R (Abcam), mouse monoclonal
anti-proliferating cell nuclear antigen (PCNA) antibody (DakoCy-
tomation, Glostrup, Denmark), and mouse monoclonal anti-type I
Collagen (COL I) (Abcam) were used to characterize the presence of
inﬂammatory and proliferative cells. The antibodies were detected
with a biotinylated goat anti-mouse IgG, which was visualized with
a horseradish peroxidase/AB complex using 3,30-diaminobenzidine
tetrahydrochloride as the chromogen (DakoCytomation, Carpin-
teria, CA, USA).
The stained area was quantiﬁed in digital photomicrographs
using the Image ProPlus 7.0 software (Media Cybernetics Inc,
Bethesda, MD, USA) and expressed as an area percentage for RAM-
11. During image acquisition, several steps were followed. First,
staining presence is evaluated at 4 magniﬁcation. Then, 10 or
20 magniﬁcations, according to need, are used to obtain the
pictures for the staining evaluation of the whole synovial
membrane. Following, Image J software is employed for the anal-
ysis of the different set of images for each sample, and only theareas with stronger staining were quantiﬁed while those areas that
looked like background or artifacts were dismissed. The total
quantiﬁcation for a given sample was the mean of several staining
intensity measurements done.
Statistical analysis
Results are expressed as mean and 95% conﬁdence interval (95%
CI; lower limit, upper limit). Data from multiple groups were
compared using ManneWhitney non-parametric analyses, as
appropriate. Correlations were evaluated using the Spearman test.
All statistical analyses were performedwith commercially available
software (SPSS v 11.0, Chicago, USA). Differences were considered
signiﬁcant when P < 0.05.
Results
Cartilage and synovial membrane histology
Synovial histological changes were evaluated by the Krenn
score. The OPOA þ VEH group presented a total Krenn synovitis
score higher than that of healthy animals [healthy 0.16 (0.3, 0.6)
vs OPOAþVEH 4.0 (2.5, 5.5); P¼ 0.003]. An increase was observed
in lining and matrix and vessel partial scores [lining score:
healthy 0.16 (0.3, 0.6) vs OPOA þ VEH 1.5 (0.9, 2.1); matrix and
vessel score: healthy 0.0 (0.0, 0.0) vs OPOA þ VEH 2.16 (1.1, 3.1);
P ¼ 0.005 and P ¼ 0.002 respectively]. No difference in inﬂam-
matory inﬁltration score was found between healthy and
OPOA þ VEH groups [healthy 0.0 (0.0, 0.0) vs OPOA þ VEH 0.33
(0.2, 0.9); P ¼ 0.138]. Notably, PTH [1-34] decreased the total
Krenn synovitis score with respect to the vehicle-treated group
[OPOA þ VEH 4.0 (2.5, 5.5) vs OPOA þ PTH 1.66 (0.4, 2.9);
P ¼ 0.017] by reducing both the lining score [OPOA þVEH 1.5 (0.9,
2.1) vs OPOA þ PTH 0.33 (0.2, 0.9), P ¼ 0.011] and the matrix and
vessel score [OPOA þ VEH 2.16 (1.1, 3.1) vs OPOA þ PTH 1.0 (1.0,
1.0), P ¼ 0.021] [Fig. 1(A)].
Cartilage histological changes were evaluated according to the
Mankin grading score. OPOA þ VEH knees had higher Mankin
scores than control knees [healthy 0.2 (0.35, 0.75) vs OPOA þVEH
4.8 (2.1, 7.5); P < 0.007]. Furthermore, PTH [1-34] administration
decreased this score relative to placebo in OPOA knees
[OPOA þVEH 4.8 (2.1, 7.5) vs OPOA þ PTH 2.4 (1.0, 3.8); P < 0.026].
In addition, a moderate but signiﬁcant correlation was observed
between the Krenn synovitis and the Mankin cartilage scores
(r ¼ 0.629; P ¼ 0.012) [Fig. 1(E)].
Correlations between subchondral bone structural parameters and
synovial histology
Subchondral bone structural parameters were well correlated
with the Krenn synovitis score. Indeed, Spearman correlation
analysis showed that B.Ar/T.Ar%, Tb.Th, and Ip were inversely
related (P < 0.05), whereas FD was directly related (P < 0.001) with
the Krenn synovitis score [Fig. 2(B)].
PTH did not affect macrophage or lymphocyte inﬁltration in synovial
membrane
Inﬂammatory inﬁltration in synovial membrane was analyzed
by studying the presence of macrophages and B and T lymphocytes.
RAM-11 immunostaining revealed that the presence of macro-
phages was increased in OPOA þ VEH and OPOA þ PTH groups
compared to healthy animals [healthy 0.01 (0.0, 0.0) vs OPOAþVEH
0.16 (0.1, 0.4) and OPOA þ PTH 0.24 (0.2, 0.7); P ¼ 0.05].
Furthermore, the PTH group did not show any signiﬁcant difference
Fig. 1. Histopathological evaluation of synovial changes. (A) The Krenn scores were obtained from the sum of partial scores evaluating the synovial lining layer enlargement, the
presence of vessels and matrix ﬁbrosis and inﬂammatory inﬁltration in synovial membranes from HEALTHY, OPOA þ VEH, and OPOA þ PTH (n ¼ 6, each group). Values are
expressed as mean  95% CI; *P < 0.05 vs HEALTHY, &P < 0.05 vs OPOA þ VEH. (BeD) Representative 10 hematoxylin-eosin staining images in synovial membranes from healthy
(B), OPOA þ VEH (C), and OPOA þ PTH (D) groups. (E) Correlation between synovitis and cartilage damage as assessed by the Krenn and Mankin scores, respectively. The analysis
was carried out by Spearman analysis using ﬁve independent samples of each group.
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Fig. 2. Subchondral bone assessment. (A) Representative qualitative 2D reconstructed from each group, by using the CTAn software (Skyscan, Aartselaar, Belgium). (B) Micro-
structural subchondral bone parameters represented as mean and 95% CI (lower limit, upper limit). Signiﬁcance differences between the groups represented by P-value have been
calculated by ManneWhitney non-parametric analyses. (C) Correlations between microstructural parameters as: bone area/tissue area fraction (B.Ar/T.Ar%), trabecular thickness
(Tb.Th), fractal dimension (FD) and polar moment of inertia (Ip) at subchondral bone and the Krenn score. Correlation coefﬁcients were obtained comparing healthy, vehicle-treated
OPOA and PTH-treated OPOA groups (n ¼ 3 for each) by Spearman bivariate analysis. *Correlation is signiﬁcant at the 0.05 level (two-tailed), and **correlation is signiﬁcant at the
0.001 level (two-tailed).
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treated group [Fig. 3(A)]. Regarding the presence of lymphocytes,
B cells were present in the animals treated with vehicle and with
PTH [Fig. 3(FeH)], while no presence of T cells was detected by
immunohistochemistry in any group.
PTH effects in pro-inﬂammatory modulators in synovial membrane
The gene and protein expression of several pro-inﬂammatory
cytokines and catabolic enzymes were examined in synovial
membranes. As illustrated in Fig. 4, MCP-1 showed higher mRNA
levels in the vehicle-treated group than in the control group [DCt
values for healthy 9.2 (10.0, 8.4) vs OPOA þ VEH 7.9 (9.0,
6.7); P ¼ 0.051]. Intermittent PTH [1-34] was able to decrease the
mRNA expression of MCP-1 compared with the vehicle-treated
group [DCt values for OPOA þ VEH 7.9 (9.0, 6.7) vs
OPOA þ PTH 9.5 (10.1, 8.8); P ¼ 0.015]. IL-1b and COX-2 mRNA
expression showed an unexpected downward trend in rabbits
treatedwith either vehicle or PTH comparedwith the healthygroup.
MMP-13 mRNA levels were up-regulated in the vehicle-treated
group relative to controls [DCt values for healthy 13.4 (16.4,
10.4) vs OPOA þ VEH 7.7 (8.9, 6.5); P ¼ 0.004], and PTH
treatment reduced these levels [OPOA þ VEH 7.7 (8.9, 6.5) vs
OPOA þ PTH 10.3 (12.4, 8.2); P ¼ 0.015]. In contrast, MMP-9
gene expression did not show any difference between groups
[DCt values for healthy 13.5 (15.0, 12.0), OPOA þ VEH 13.2
(13.6, 12.8), OPOA þ PTH 13.5 (15.4, 11.5); P > 0.05 in all
cases].
PTH counteracts synovial ﬁbrosis
To indicate the grade of ﬁbrosis in synovial membrane, we
have analyzed Col1A1 gene expression and type I collagenimmunostaining. The vehicle-treated group displayed increased
Col1A1 mRNA expression compared with control animals [DCt
values for healthy 3.2 (4.4, 1.9) vs OPOA þ VEH 0.6 (0.26, 0.9);
P < 0.004]. In turn, PTH [1-34] treatment decreased the mRNA
expression of Col1A1 relative to vehicle administration
[OPOA þ VEH 0.6 (0.26, 0.9) vs OPOA þ PTH 1.2 (2.5, 0.03);
P < 0.008] [Fig. 5(A)].
Likewise, immunohistochemical studies of synovial membrane
demonstrated an increased staining for type I collagen in the
vehicle-treated group vs controls, while PTH [1-34] decreased this
expression when compared with vehicle [Fig. 5(BeD)].
PTH 1 receptor expression in synovial membrane
PTH1R synthesis in synovial membrane tended to be higher in
OPOA þ VEH rabbits than in the control group [healthy 1.25 (0.2,
2.3) vs OPOAþVEH 2.5 (0.9, 5.9); P> 0.05]. Likewise, intermittent
treatment with PTH [1-34] did not signiﬁcantly decrease the
synthesis of this receptor [OPOA þ VEH 2.5 (0.9, 5.9) and
OPOA þ PTH 2.1 (0.8, 3.3); P > 0.05] [Fig. 6(A)].
Immunohistochemistry showed that PTH1R is mainly located
around the vessels of synovial membranes from control rabbits,
whereas this receptor is located in the lining cells of synovial
membranes from rabbits treated with vehicle. Interestingly, we
have found in the synovial membranes of PTH-treated rabbits the
presence of PTH1R again concentrated around the vessels
[Fig. 6(BeG)].
PTH effects on synoviocyte proliferation
The lining thickness is related to the synoviocyte proliferation.
Thus, the lining thickness was lower in the healthy group than in
vehicle-treated animals [healthy 21.7 (19.6, 23.8) vs OPOA þ VEH
Fig. 3. Inﬂammatory inﬁltration in synovial membranes. (A) Dot blots representing the percentage of RAM-11-stained area per total tissue surface analyzed in synovial membranes
from HEALTHY, OPOA þVEH, and OPOA þ PTH (n ¼ 5, each group). Values are expressed as mean  95% CI; *P < 0.05 vs HEALTHY (upper panel). (BeE) Representative (20) images
of speciﬁc macrophage staining by RAM-11 antibody in synovial membranes from HEALTHY (B), OPOA þ VEH (C), OPOA þ PTH (D) and negative control (E). (FeI) Representative
(10) images of B lymphocyte inﬁltration staining in synovial membranes from HEALTHY (F), OPOA þ VEH (G), OPOA þ PTH (H) and negative control (I).
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the lining thickness signiﬁcantly compared to vehicle administra-
tion [OPOA þVEH 53.9 (36.4, 71.4) vs OPOA þ PTH 31.3 (20.1, 42.5);
P ¼ 0.031] [Fig. 7(A)].
PCNA-stained cells in the synovial membrane were scarce in
healthy animals, while these cells were profuse in VEH þ OPOA
rabbits and markedly lesser in the PTH-treated animals compared
to vehicle-treated animals [Fig. 7(BeD)].
Discussion
Our study is the ﬁrst to demonstrate the beneﬁcial effects of
intermittent administration of PTH [1-34] in synovial changes thatoccur in a rabbit model of OA preceded by OP. Synovial hyperplasia,
increased ﬁbrosis-related alterations, and a modest inﬂammatory
inﬁltration were observed in this animal model, as assessed by the
Krenn score24. Notably, this synovitis score showed signiﬁcant
correlations with cartilage damage and subchondral bone micro-
structure deterioration. The lining and subintimal changes in the
synovitis score were counteracted by intermittent PTH [1-34]
administration. In addition, PTH decreased the synovial expres-
sion of the proﬁbrotic type I collagen and the catabolic mediators
MCP-1 and MMP-13, but did not alter synovial inﬂammatory
macrophage inﬁltration. PTH also lowered lining thickness and
PCNA staining, suggesting a negative effect on synoviocyte
proliferation.
Fig. 4. PTH effects in pro-inﬂammatory modulators in synovial membrane. (A) Dot blots showing DCt of IL-1b, MCP-1, COX-2, MMP-9, and MMP-13 mRNA expression in synovial
membranes from HEALTHY (n ¼ 5), OPOA þ VEH (n ¼ 6), and OPOA þ PTH (n ¼ 6) knees. Values are expressed as mean  95% CI; *P < 0.05 vs HEALTHY, &P < 0.05 vs OPOA þ VEH.
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the synovial lining cell layer as well as increased matrix and vessels
related with ﬁbrosis in the present experimental model. This
ﬁnding is consistent with the subintimal ﬁbrosis and vascularity
clearly predominant in the synovium of OA sheep at 6 months
following meniscectomy17, and the moderate synovial hyperplasia
and initial ﬁbrosis described in patients with early OA5,25. Notably,
PTH [1-34] decreased both synovial hyperplasia and ﬁbrosis-
related changes in matrix and vessels.
A low degree of inﬂammatory inﬁltration was found in synovial
membranes of vehicle-treatedOPOA animals displaying the presence
of macrophages and B lymphocytes, in accordance with the inﬂam-
matory synoviopathy present in a subset of OA patients3,4,26e30.
Essentially, OA inﬁltrates differ from rheumatoid inﬁltrates in that
they exhibit lower overall cellularity and number of macrophages,
plasma cells, and CD4 T cells5,31. PTH [1-34] administration did not
exert any effect on the inﬂammatory inﬁltration score ormacrophage
or lymphocyte presence in the synovial membrane.
MCP-1 mRNA expression as well as MMP-9 and -13 protein
expression were signiﬁcantly increased in the synovial membrane
of vehicle-treated OPOA animals, thus denoting the relevant
synovial cell activity. MCP-1 is an important chemokine mostly
expressed by synovial macrophages26 and ﬁbroblasts29, promoting
the inﬂux and activation of monocytes in both inﬂamed RA and OA
joints32. Likewise, synovial ﬁbroblast-synthesized MMP-9 and -13
are two of themost activeMMPs involved in the physiopathology of
OA tissue damage12,26,33,34. The increase of these inﬂammatory and
matrix-degrading mediators in the synovium may have markedly
contributed to cartilage damage as reﬂected in the direct rela-
tionship between synovitis and cartilage damage in our rabbits
with OA preceded by OP.
In the absence of a signiﬁcant change in the inﬂammatory
inﬁltration score, the reduction of MCP-1 production in the PTH-
treated group may be explained by the fact that MCP-1 is impor-
tantly produced by type B synoviocytes in knee OA29 and by
vascular endothelial cells, as described in rheumatoid synovium35.Indeed, the role of type B synoviocytes in the PTH effect on MCP-1
expression is supported by the evidence of a decreased synovial
lining proliferation in the absence of effect on macrophage and
lymphocyte presence in our PTH-treated OPOAmembranes. Type B
synoviocytes have shown to express PTH/PTHrP receptors in OA
synovium16. The role of the endothelial cells is suggested by both
the decrease of neoangiogenesis and their important expression of
PTH1R in our OPOA rabbits. Endothelial cells express PTH/PTHrP in
rheumatoid synovium36. Overall, it seems that the intimal prolif-
eration contributes more to OA synoviopathy than sublining
inﬂammatory cell inﬁltration, and most of the MCP-1 likely comes
from ﬁbroblast-like type B synoviocytes in OA synovium.
Synovial ﬁbrosis occurs in differing degrees throughout the OA
process. Resident ﬁbroblasts under the inﬂux of altered intracel-
lular molecular mechanisms deposit an excess of extracellular
matrix (ECM) components, mainly type I collagen, at intimal and
subintimal tissues37. Accordingly, an increase of mRNA expression
of collagen, type 1, alpha 1 was determined in the synovium of our
OPOA animals and PTH [1-34] decreased its synovial expression.
This and the immunohistochemical studies suggest that type I
collagen plays a main role in ﬁbrosis-related changes of OPOA
synovium. Our ﬁndings are in agreement with previous publica-
tion, where a constitutively active PTH1R expressed only by
vascular smooth muscle cells inhibited aortic type I collagen and
calcium accrual, and enhanced vessel distensibility in diabetic low-
density lipoprotein receptor (LDLR)-deﬁcient mice38. In contrast, it
is well known that PTH mostly up-regulate type I collagen in other
cells such as osteoblast and kidney cells39. In this sense, our data
provide a potential mechanism for improving joint mobility and
function in OA.
PTHrP is a multifunctional peptide that elicits vasodilatory
responses in different vascular beds40. Synovial PTH1R protein
levels tended to increase in OPOA þ VEH animals and to diminish
after PTH treatment indicating some effect of PTH in the OPOA
synovial membrane. Since PTH1R expression shifts between vessel
and synovial cells in the experimental groups, it is expected that
Fig. 5. PTH counteracts ﬁbrosis associated with OA. (A) Dot blots displaying DCt of Collagen, type I, alpha 1 (Col1A1) mRNA expression in synovial membranes from
HEALTHY (n ¼ 5), OPOA þ VEH (n ¼ 6), and OPOA þ PTH (n ¼ 6) groups. Values are expressed as mean  95% CI; *P < 0.05 vs HEALTHY, &P < 0.05 vs OPOA þ VEH. (BeE)
Representative (10) images of immunohistochemistry for type I Collagen in synovial membranes from HEALTHY (B), OPOA þ VEH (C), OPOA þ PTH (D) and negative control (E).
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already shown in bone rats following intermittent administration
of PTH41. PTH1R was mainly expressed around the vessels of
synovial membranes in control and PTH-treated OPOA rabbits. In
contrast, the PTH/PTHrP receptor switched its location to the
synovial lining cells in vehicle-treated OPOA rabbits. Takentogether, these results are consistent with a possible paracrine
pathway for PTHrP action in the synovial microcirculation, wherein
PTHrP peptides secreted by the synovial endothelium could act on
surrounding PTH1R-positive pericytes and smooth muscle cells36.
Synovial cell proliferation as estimated by lining cell score,
lining thickness and PCNA immunostaining was increased in
Fig. 6. PTH1R expression in synovial membrane. (A) Bar graph showing a densitometric analysis of PTH1R protein synthesis in synovial membranes from HEALTHY, OPOA þ VEH
and OPOA þ PTH (n ¼ 4, each group), as assessed by Western blot. Results are expressed as mean  95% CI; *P < 0.05 vs HEALTHY. To the right, representative images of the Western
blot for PTH1R and Actin (as loading control) in synovial membranes of each group. (BeG) Immunohistochemistry analysis of PTH1R at 5 mm thick synovial membranes. Repre-
sentative (20) images for HEALTHY (B,E), OPOA þ VEH (C,F), and OPOA þ PTH (D,G) knees are displayed showing PTH1R localization whether in lining layer (upper panel) or in
vessels (lower panel). (HeK) Representative images (40) of PTH1R-stained lining layer area (H), PTH1R-stained blood vessel (J), and respective negative controls (IeK).,
Fig. 7. Evaluation of synovial cell proliferation. (A) Dot blots representing the lining thickness in A.U (pixels) analyzed in synovial membranes from HEALTHY, OPOA þ VEH,
OPOA þ PTH groups (n ¼ 5, each group). Values are expressed as mean  95% CI; *P < 0.05 vs HEALTHY, and &P < 0.05 vs OPOA. (BeE) Representative (20) images of speciﬁc PCNA
staining in synovial membranes from HEALTHY (B), OPOA þVEH (C), OPOA þ PTH (D) and negative control (E). A 40 image of synovial membrane from OPOA þVEH shows nuclear
PCNA staining.
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intima of the synovium. Synoviocyte proliferation and activation
likely occur in response to increased demands for clearance of
molecular debris in OA synovial ﬂuid42. Interestingly, there was no
hyperplasia in healthy membranes although it was increased in
OPOA þ VEH synovial membranes and reduced after treatment
with PTH. Since hyperplasia is likely correlated with synovial cell
proliferation, our data suggest that there was less proliferation in
the PTH-treated model compared to vehicle-treated group.
Furthermore, the PCNA staining changes go in the same line of
evidence than the decrease of both Krenn score and the lining
thickness data, indicating an inhibitory PTH effect on lining cell
proliferation. Indeed, the potential antiproliferative action of PTH
on PTH1R-expressing cells, such as type B synoviocytes or endo-
thelial cells in contrast than its lack of effect on synovial macro-
phage presence, might suggest a synovial cell-speciﬁc action of PTH
in OA synoviopathy.
Therefore, in the present study, we have characterized the
histopathological features of the existent synoviopathy in our
rabbit model of OA with altered subchondral bone integrity.Notably, this synoviopathy correlated well with cartilage damage
and subchondral bone microstructure impairment. Altogether, this
and other studies show that PTH may ameliorate OA through
favorable global effects on the three most affected tissues, by
improving subchondral bone integrity20, inhibiting cartilage
degradation15,43 and exerting certain beneﬁcial effects on synovial
changes. Since these joint tissues are closely interrelated, a beneﬁ-
cial direct action on any of them leads to beneﬁt in the others, and
ﬁnally contribute to counteract the development and progression
of OA. In addition, we have demonstrated direct beneﬁcial effects of
PTH upon the synovium of this experimental model. Thus, inter-
mittent PTH [1-34] administration might hold a potential as ther-
apeutic option for synoviopathy associatedwith OA. Further studies
are warranted to explore the concrete mechanisms of PTH action in
joint tissues during the OA process.
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